Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development
Partnership leverages artificial intelligence to accelerate discovery of next-generation treatments for obesity and cardiometabolic diseases Eli Lilly (LLY) has entered ...



















